The Patent Finder
CF

Chdi Foundation, Inc.

First filing 2007
OverviewNotableFeesChangesFamiliesPatent listSources & methods

49 patents currently held

3 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Jan 2027. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
4
Ending by 2030
Jan 2027
Next term end
33
Patent families

When these terms end

Held patents by the year their term ends
notable patents fee due within 90 days all others Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Dec 27, 2026
    The maintenance fee for Atm Kinase Inhibitors and Compositions and Methods of Use Thereof (US 11,685,734) comes due Dec 27, 2026. Unpaid by Jun 28, 2027, it lapses early.
  • 3 fees due Apr 1 to 29, 2027 · next Apr 1
  • 2 fees due May 7 to 19, 2027 · next May 7
  • 2 fees due Jun 10 to 26, 2027 · next Jun 10
  • 1 fee due Sep 5, 2027
    The maintenance fee for Heterocyclic Compounds and Imaging Agents for Imaging Huntingtin Protein (US 11,918,662) comes due Sep 5, 2027. Unpaid by Mar 6, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

What they patent

The 5 largest of its 33 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.

Patents held now

Soonest term end first.
PatentTitleStatusExpiresConfidence
US 10,738,307Compositions and Their Uses Directed to Huntingtin
In force
 · Medium confidence
In forceMedium confidence
US 12,509,681Antisense Oligonucleotides Directed to Huntingtin
In force
 · Medium confidence
In forceMedium confidence
US 8,536,186Certain KYNURENINE-3-Monooxygenase Inhibitors, Pharmaceutical Compositions, and Methods of Use Thereof
In force
 · High confidence
In forceHigh confidence
US 8,946,197Transglutaminase TG2 Inhibitors, Pharmaceutical Compositions, and Methods of Use Thereof
In force
 · High confidence
In forceHigh confidence
US 8,883,785Certain KYNURENINE-3-Monooxygenase Inhibitors, Pharmaceutical Compositions, and Methods of Use Thereof
In force
 · High confidence
In forceHigh confidence
US 8,889,716Transglutaminase TG2 Inhibitors, Pharmaceutical Compositions, and Methods of Use Thereof
In force
 · High confidence
In forceHigh confidence
US 9,649,310Certain KYNURENINE-3-Monooxygenase Inhibitors, Pharmaceutical Compositions, and Methods of Use Thereof
In force
 · High confidence
In forceHigh confidence
US 10,442,782KYNURENINE-3-Monooxygenase Inhibitors, Pharmaceutical Compositions, and Methods of Use Thereof
In force
 · Medium confidence
In forceMedium confidence
US 10,501,433KYNURENINE-3-Monooxygenase Inhibitors, Pharmaceutical Compositions, and Methods of Use Thereof
In force
 · Medium confidence
In forceMedium confidence
US 9,505,736Histone Deacetylase Inhibitors and Compositions and Methods of Use Thereof
In force
 · High confidence
In forceHigh confidence
10 of 49 patents shown.
Pro members see all 49.
Pro members: see all 49 patents
Also on record, not counted in the 49: 3 patents in force now held by others · 1 patent ended · 2 applications pending · 9 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited